BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamamoto-Furusho JK, Al Harbi O, Armuzzi A, Chan W, Ponce de Leon E, Qian J, Shapina M, Toruner M, Tu CH, Ye BD, Guennec M, Sison C, Demuth D, Fadeeva O, Khan QMR. Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study. Dig Liver Dis. 2020;52:869-877. [PMID: 32563721 DOI: 10.1016/j.dld.2020.05.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Dave MB, Dherai AJ, Desai DC, Mould DR, Ashavaid TF. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience. Eur J Clin Pharmacol 2021;77:55-62. [PMID: 32803288 DOI: 10.1007/s00228-020-02975-0] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bargo D, Tritton T, Cappelleri JC, DiBonaventura M, Smith TW, Tsuchiya T, Gardiner S, Modesto I, Holbrook T, Bluff D, Kobayashi T. Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use. Inflamm Intest Dis 2021;6:186-98. [PMID: 35083284 DOI: 10.1159/000519123] [Reference Citation Analysis]
3 Hyun HK, Zhang H, Yu J, Kang EA, Park J, Park SJ, Park JJ, Kim TI, Kim WH, Cheon JH. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02225-w] [Reference Citation Analysis]
4 Yoon J, Kim DS, Kim YJ, Lee JW, Hong SW, Hwang HW, Hwang SW, Park SH, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK. Risk factors and prognostic value of acute severe lower gastrointestinal bleeding in Crohn’s disease . World J Gastroenterol 2021; 27(19): 2353-2365 [PMID: 34040327 DOI: 10.3748/wjg.v27.i19.2353] [Reference Citation Analysis]
5 Li J, Liu Z, Hu P, Wen Z, Cao Q, Zou X, Chen Y, Wang Y, Zhong J, Shen X, Demuth D, Fadeeva O, Xie L, Chen J, Qian J. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study. BMC Gastroenterol 2022;22:44. [PMID: 35120446 DOI: 10.1186/s12876-021-02074-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]